The latest updates on our research and how it is improving people’s lives.
Clinical trial finds Azithromycin has no benefit against COVID-19
6 May 2021
A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.
Study reveals the three most important aspects of care for hip fractures
5 May 2021
Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.
Major ERC funding awarded to Professor Michael Dustin
4 May 2021
Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.
The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19
30 April 2021
Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?
Professor Michael Dustin elected to the National Academy of Sciences
29 April 2021
Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.
Small mechanical forces in immune cells measured at unprecedented sensitivity
16 April 2021
Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.
NDORMS researchers awarded for Dupuytren research
8 April 2021
Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.
Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF
11 March 2021
New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).
A new study maps the expression of innate immune receptors during the course of arthritis
8 March 2021
The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.
International Women's Day
8 March 2021
It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.
Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints
5 March 2021
Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.
NDORMS academics named NIHR Senior Investigators
5 March 2021
Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).
New centre aims to help companies conduct more efficient trials
26 February 2021
A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.
Cognitive–behavioural therapy consistently improves quality of life
26 February 2021
Main Rehabilitation and self-management Research
A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.
Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders
19 February 2021
The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec
19 February 2021
Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.
Study reveals the safety of bisphosphonates in chronic kidney disease
10 February 2021
The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.
WHiTE Four trial results published
9 February 2021
Hip Main Orthopaedics and trauma Research Trauma
The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.
Vascular loss shown to be the primary hallmark of aging
4 February 2021
Kennedy Main Tissue remodelling and regeneration
New Research from the Kusumbe group at the Kennedy Institute of Rheumatology identifies vascular attrition, marked by pericyte to fibroblast differentiation, as a primary hallmark of aging and highlights organ-specific vascular changes with age.
Understanding the first wave of COVID-19 and implications for tackling the ongoing pandemic: evidence from 5.5 million people from Catalonia, Spain
3 February 2021
Botnar Main Research Statistics and epidemiology
Health outcomes during the first wave of COVID-19 in Catalonia, Spain, have been described in detail in a study published by Nature Communications.